BioMarin Pharmaceutical Inc.
BMRN
$62.34
-$5.14-7.62%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 426.86M | 322.29M | 256.59M | 205.46M | 167.65M |
| Total Depreciation and Amortization | 96.43M | 99.68M | 106.36M | 105.32M | 104.39M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 265.95M | 223.09M | 195.42M | 194.68M | 223.77M |
| Change in Net Operating Assets | -216.40M | -230.36M | -229.50M | -225.28M | -336.54M |
| Cash from Operations | 572.84M | 414.70M | 328.86M | 280.16M | 159.26M |
| Capital Expenditure | -85.42M | -94.81M | -98.08M | -98.34M | -96.69M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 221.92M | 89.94M | 63.57M | 2.87M | -14.55M |
| Cash from Investing | 136.49M | -4.88M | -34.52M | -95.47M | -111.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -494.99M | -494.99M | 1.58M | 972.00K | 0.00 |
| Issuance of Common Stock | 49.28M | 56.22M | 55.78M | 55.38M | 69.35M |
| Repurchase of Common Stock | -77.56M | -76.57M | -75.20M | -74.85M | -76.32M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.18M | -3.13M | -2.29M | -2.29M | -11.76M |
| Cash from Financing | -526.45M | -518.47M | -20.13M | -20.78M | -18.73M |
| Foreign Exchange rate Adjustments | 4.83M | -1.32M | 3.55M | 3.01M | 1.31M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 187.72M | -109.97M | 277.77M | 166.92M | 30.60M |
